Literature DB >> 26189039

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.

Siqin Ye1, Bin Cheng2, Gregory Y H Lip3, Richard Buchsbaum2, Ralph L Sacco4, Bruce Levin2, Marco R Di Tullio5, Min Qian2, Douglas L Mann6, Patrick M Pullicino7, Ronald S Freudenberger8, John R Teerlink9, J P Mohr10, Susan Graham11, Arthur J Labovitz12, Conrado J Estol13, Dirk J Lok14, Piotr Ponikowski15, Stefan D Anker16, John L P Thompson2, Shunichi Homma5.   

Abstract

We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. Proportional hazards models were used to test whether each score predicted major bleeding, and comparison of different risk scores was performed using Harell C-statistic and net reclassification improvement index. For the warfarin arm, both scores predicted bleeding risk, with OBRI having significantly greater C-statistic (0.72 vs 0.61; p = 0.03) compared to HAS-BLED, although the net reclassification improvement for comparing OBRI to HAS-BLED was not significant (0.32, 95% confidence interval [CI] -0.18 to 0.37). Performance of the OBRI and HAS-BLED risk scores was similar for the aspirin arm. For participants with OBRI scores of 0 to 1, warfarin compared with aspirin reduced ischemic stroke (hazard ratio [HR] 0.51, 95% CI 0.26 to 0.98, p = 0.042) without significantly increasing major bleeding (HR 1.24, 95% CI 0.66 to 2.30, p = 0.51). For those with OBRI score of ≥2, there was a trend for reduced ischemic stroke with warfarin compared to aspirin (HR 0.56, 95% CI 0.27 to 1.15, p = 0.12), but major bleeding was increased (HR 4.04, 95% CI 1.99 to 8.22, p <0.001). In conclusion, existing bleeding risk scores can identify bleeding risk in patients with HFrEF in SR and could be tested for potentially identifying patients with a favorable risk/benefit profile for antithrombotic therapy with warfarin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26189039      PMCID: PMC4554775          DOI: 10.1016/j.amjcard.2015.06.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.

Authors:  Gregory Y H Lip; Felicita Andreotti; Laurent Fauchier; Kurt Huber; Elaine Hylek; Eve Knight; Deirdre A Lane; Marcel Levi; Francisco Marin; Gualtiero Palareti; Paulus Kirchhof; Jean-Philippe Collet; Andrea Rubboli; Daniela Poli; John Camm
Journal:  Europace       Date:  2011-05       Impact factor: 5.214

2.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

3.  Warfarin in heart failure.

Authors:  John W Eikelboom; Stuart J Connolly
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

4.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

5.  The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Authors:  Vanessa Roldán; Francisco Marín; Sergio Manzano-Fernández; Pilar Gallego; Juan Antonio Vílchez; Mariano Valdés; Vicente Vicente; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2013-09-18       Impact factor: 24.094

6.  Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.

Authors:  Shunichi Homma; John L P Thompson; Alexandra R Sanford; Douglas L Mann; Ralph L Sacco; Bruce Levin; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; Susan Graham; J P Mohr; Barry M Massie; Arthur J Labovitz; Marco R Di Tullio; André P Gabriel; Gregory Y H Lip; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker
Journal:  Circ Heart Fail       Date:  2013-07-23       Impact factor: 8.790

7.  Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Authors:  Jonas Oldgren; Marco Alings; Harald Darius; Hans-Christoph Diener; John Eikelboom; Michael D Ezekowitz; Gabriel Kamensky; Paul A Reilly; Sean Yang; Salim Yusuf; Lars Wallentin; Stuart J Connolly
Journal:  Ann Intern Med       Date:  2011-11-15       Impact factor: 25.391

8.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

9.  Warfarin and aspirin in patients with heart failure and sinus rhythm.

Authors:  Shunichi Homma; John L P Thompson; Patrick M Pullicino; Bruce Levin; Ronald S Freudenberger; John R Teerlink; Susan E Ammon; Susan Graham; Ralph L Sacco; Douglas L Mann; J P Mohr; Barry M Massie; Arthur J Labovitz; Stefan D Anker; Dirk J Lok; Piotr Ponikowski; Conrado J Estol; Gregory Y H Lip; Marco R Di Tullio; Alexandra R Sanford; Vilma Mejia; Andre P Gabriel; Mirna L del Valle; Richard Buchsbaum
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

10.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

View more
  2 in total

1.  CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.

Authors:  Siqin Ye; Min Qian; Bo Zhao; Richard Buchsbaum; Ralph L Sacco; Bruce Levin; Marco R Di Tullio; Douglas L Mann; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; J P Mohr; Susan Graham; Arthur J Labovitz; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Gregory Y H Lip; John L P Thompson; Shunichi Homma
Journal:  Eur J Heart Fail       Date:  2016-07-21       Impact factor: 15.534

2.  Anticoagulation versus placebo for heart failure in sinus rhythm.

Authors:  Eduard Shantsila; Monika Kozieł; Gregory Yh Lip
Journal:  Cochrane Database Syst Rev       Date:  2021-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.